MétaCan
Menu
Back to cohort
Record W4403391613 · doi:10.1136/gutjnl-2024-basl.38

P29 Second line treatment for primary biliary cholangitis( PBC) with obeticholic acid – A real world data from Wales

2024· article· en· W4403391613 on OpenAlexaboutno aff
Irfan Ullah, Rishab Avasarala, Areeb Khan, Bradley Arms-Williams, Andrew D. Yeoman, David Samuel, Thiriloganathan Mathialahan, Ian Rees, Brijesh Srivastava

Bibliographic record

Venuenot available
Typearticle
Languageen
FieldMedicine
TopicLiver Diseases and Immunity
Canadian institutionsnot available
Fundersnot available
KeywordsObeticholic acidMedicineInternal medicineGastroenterologyLine (geometry)Mathematics

Abstract

fetched live from OpenAlex

Obeticholic acid (OCA) is indicated in patients with primary biliary cholangitis (PBC) that have failed or are intolerant to therapeutic dose of Ursodeoxycholic acid (UDCA).Optimal weight-based dosing of UDCA is essential before considering second-line treatment. We present real-world data of our experience with OCA treatment in Wales between Aug 2018– April 2024.A virtual MDT panel was set-up, compared with a spoke-hub model used elsewhere. Referral form is sent electronically to the MDT panel which consists of a hepatologist from each of the six health boards in Wales. Treatment is initiated and monitored by the referring clinician. Modified Toronto criteria (ALP < 1.67 x upper limit of normal (ULN)) is used to define biochemical response to OCA. Out of 111 referrals received, 99 were approved for OCA use. Median age at the time of referral was 55 years and 91% were females. 101 (91%) were on optimal UDCA dose, while 10 (9%) were intolerant to UDCA. Median ALP prior to commencing OCA was 490 (215–1037). 26/111 patients had cirrhosis( 23%).47% of patients had documented pruritus(n=52). 6 patients had severe pruritus of which 3 did not commence OCA while 2 patients were started on low dose. Out of 99 patients approved for OCA,11 patients did not start treatment due to fear of side effects, while in 11 patients OCA was stopped within median duration of 6 months due to adverse events( mostly pruritis).Complete follow-up data after 12 months of OCA treatment was available for 58/99 patients. Out of these,32 patients were on 5 mg OD OCA, 18 patients on 10 mg OD and 5 patients on 5 mg three times per week at 12 months period while for the remaining 3 patients, OCA dose was unknown. 30/58 (51%) patients achieved biochemical response with OCA. At 12 months, median ALP in the OCA responsive group was 185(91–249), and median ALP in the OCA non-responsive group was 436(280–1057). Response rate with OCA in Wales are similar to that reported in POISE trial.Use of second-line treatment with OCA is consistent and accessible across Wales, facilitated by our virtual MDT set-up. Patients remain under the care of their local clinician maintaining continuity of care. Overall, virtual monitoring of 12-month response after starting OCA can be challenging as it is reliant on receiving follow-up data from the referring clinician. Patients who fail to respond to OCA must be considered for other second line treatment options including Bezafibrate.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.016
Threshold uncertainty score0.031

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.001
Science and technology studies0.0010.000
Scholarly communication0.0010.000
Open science0.0000.001
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0040.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.072
GPT teacher head0.329
Teacher spread0.256 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2024
Admission routes1
Has abstractyes

Explore more

Same topicLiver Diseases and ImmunityFrench-language works237,207